Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Menactra
- Development stage
- Approved
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Menactra is a quadrivalent meningococcal conjugate vaccine developed by Sanofi for active immunization against invasive disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. Each 0.5 mL intramuscular dose contains 4 mcg of each serogroup-specific capsular polysaccharide conjugated to approximately 48 mcg total diphtheria toxoid carrier protein. The conjugate design elicits functional bactericidal antibodies and immunologic memory against the included meningococcal serogroups; it does not protect against serogroup B disease. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4d8781ff-9366-462c-8161-6e958f44fcb4))
- Brand names
- Menactra
- Other names
- MenACWY-DMeningococcal groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccineTetraMenD
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on Menactra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Menactra.